The global xerostomia (Dry Mouth) treatment market size is expected to reach US$ 1.2 billion in 2026 and US$ 1.9 billion by 2033, growing at a CAGR of 6.3% between 2026 and 2033. It is expanding steadily due to the rising prevalence of dry mouth caused by aging, medication side effects, cancer therapies, and chronic diseases such as diabetes and Sjögren’s syndrome.

Treatment options include saliva substitutes, saliva stimulants, prescription drugs, and over-the-counter oral care products like sprays, gels, and lozenges. Increasing awareness of oral hygiene and the complications associated with untreated xerostomia, such as dental caries and swallowing difficulties, is supporting market growth. Improved product formulations, broader pharmacy availability, and growing demand for patient-friendly long-term symptom management continue to drive global market expansion.

Drivers - Rising Polypharmacy and Medication-Induced Xerostomia in Aging Patient Populations

Drug-induced xerostomia is the most common cause of dry mouth in clinical practice, and the growing global trend of polypharmacy among older adults is a primary structural demand driver for xerostomia treatment products. The American Dental Association (ADA) identifies over 400 medications as known causative agents of xerostomia, including antihistamines, antidepressants, antihypertensives, diuretics, and anticholinergic drugs, all of which are widely prescribed to the aging population.

According to the United Nations, the global population aged 60+ will reach 2.1 billion by 2050, with the concurrent rise in multi-drug prescriptions driving proportional xerostomia prevalence. A cross-sectional study published in Gerodontology confirmed a prevalence of xerostomia exceeding 40% among institutionalized elderly patients. This demographic-pharmacological intersection creates a persistently expanding patient population requiring long-term xerostomia symptom management through saliva substitutes and stimulants, generating recurring market demand.

Head and Neck Cancer Treatment Driving Severe Xerostomia in High-Need Clinical Populations

Radiation therapy targeting head and neck cancers, a treatment received by approximately 65,000-70,000 patients annually in the United States alone per the National Cancer Institute (NCI) is among the most severe causes of xerostomia, with radiation-induced salivary gland damage causing permanent or prolonged dry mouth in the majority of treated patients.

The World Health Organization (WHO)'s Global Cancer Observatory (GLOBOCAN) reported approximately 890,000 new head and neck cancer cases globally in 2022, creating a large and medically underserved xerostomia patient population requiring intensive, long-term treatment. Prescription pilocarpine (Salagen®) and cevimeline (Evoxac®), FDA-approved parasympathomimetic saliva stimulants, are the established pharmaceutical treatments for radiation-induced xerostomia, and the growing volume of head and neck cancer patients creates structural demand for both pharmacological and OTC xerostomia treatment products globally.

Market Restraints

Limited Efficacy and Short Duration of Action of Available Symptomatic Treatments

A primary constraint limiting the Xerostomia Treatment market's full growth potential is the acknowledged limited efficacy and short duration of action of currently available palliative products. Saliva substitutes provide temporary relief lasting minutes to a few hours, and their symptomatic rather than curative mechanism means patients require frequent reapplication throughout the day, creating adherence challenges that reduce product satisfaction and ongoing utilization.

A systematic review published in the Cochrane Database of Systematic Reviews concluded that while saliva substitutes provide some relief, evidence for the significant superiority of any single product over another remains limited, complicating physician recommendations and payer reimbursement arguments and constraining premium product pricing power.

Low Disease Awareness and Underdiagnosis Suppressing Treatment-Seeking Rates

Despite high prevalence of xerostomia, low patient and clinician awareness of dedicated treatment options beyond general hydration advice suppresses treatment-seeking rates and limits market volume growth to below theoretical demand potential. Many patients attribute dry mouth symptoms to aging or existing conditions rather than recognizing them as treatable, and a significant proportion of healthcare providers, including general practitioners and nurses, do not routinely screen for or address xerostomia during clinical consultations.

The American Academy of Oral Medicine (AAOM) has noted diagnostic gaps in the identification of xerostomia in primary care settings, particularly among elderly and medicated patients, who are most affected, thereby suppressing market demand relative to the actual disease burden.

Market Opportunities

OTC Drugs Segment as the Fastest-Growing Revenue Category Driven by Self-Care Trends

The Over-the-counter (OTC) Drugs segment is the fastest-growing product type in the Xerostomia Treatment market, offering exceptional commercial opportunities for consumer healthcare companies investing in branded, accessible dry-mouth relief products. The global trend toward self-care and OTC healthcare, accelerated by the COVID-19 pandemic and the resulting rise in pharmacy-based consumer health spending, is driving consumers toward pharmacy-accessible dry mouth management products that do not require physician visits.

The Consumer Healthcare Products Association (CHPA) reports consistent growth in OTC oral health products, and dedicated xerostomia OTC product lines, including Biotène® (now part of GlaxoSmithKline's Sensodyne Dry Mouth portfolio) and ACT Dry Mouth Rinse, are expanding their market presence through pharmacy chain partnerships and growing digital marketing. The FDA's OTC monograph framework facilitates efficient regulatory compliance for new entrants to the xerostomia product market, reducing barriers to OTC market participation.

Innovation in Sustained-Release Formulations and Electrical Salivary Gland Stimulation Devices

Two innovative technological frontiers are creating significant new market opportunities within the Xerostomia Treatment landscape: sustained-release mucoadhesive formulations and electrical neurostimulation-based salivary stimulation devices. Saliwell Ltd.'s GenNarino® device, an intraoral electrical neurostimulator that delivers low-level electrical stimulation to the lingual nerve to trigger salivary gland output, represents a paradigm shift from purely palliative to active salivation-stimulating therapy without systemic side effects.

Clinical data published in the Journal of Oral Pathology & Medicine demonstrated meaningful improvements in salivary flow with electrical stimulation approaches. Simultaneously, mucoadhesive sustained-release tablet and gel formulations that retain active ingredients at the oral mucosal surface for extended relief periods are under active development by companies including Midatech Pharma and Orahealth Corporation. These innovation platforms represent premium product differentiation opportunities in an otherwise largely commodity dry mouth product market.

Product Type Insights

Saliva stimulants lead the xerostomia treatment market by product type, commanding approximately 42% of total market share in 2025. This leadership reflects the clinical preference for treatments that address the underlying functional deficit, stimulating residual salivary gland activity rather than merely substituting for absent saliva. Prescription saliva stimulants, including pilocarpine (Salagen®) and cevimeline (Evoxac®), both FDA-approved for radiation- and Sjögren's syndrome-induced xerostomia, generate high per-unit revenue, while OTC stimulant products, including malic acid-containing lozenges and xylitol-based chewing gums, represent high-volume consumer healthcare sales.

The Sjögren's Foundation estimates that approximately 4 million Americans have Sjögren's syndrome, with xerostomia as a cardinal symptom, driving significant prescription saliva stimulant demand. Growing evidence supporting the effectiveness of muscarinic receptor agonist therapy across multiple xerostomia etiologies sustains the stimulant category's dominant market position.

Formulation Insights

Oral Sprays represent the leading formulation segment in the Xerostomia Treatment market, accounting for approximately 40% of total formulation revenue in 2025. Oral spray's market leadership is rooted in its operational convenience and rapid symptom relief, enabling patients to discreetly apply dry mouth treatment at any time and location without requiring water or food. The portable, on-demand nature of spray formulations aligns optimally with xerostomia's characteristic throughout-the-day symptom pattern.

Patients frequently experience dry mouth during professional activities, meals, and overnight periods. Biotène® Dry Mouth Oral Rinse and spray products have established a strong consumer brand recognition globally. Clinical accessibility with no prescription required, widely available in retail pharmacies and online, reinforces the oral spray formulation's dominant commercial position across both OTC saliva substitute and stimulant product categories.

Distribution Channel Insights

Retail pharmacies represent the leading distribution channel in the xerostomia treatment market, accounting for approximately 46% of total channel revenue in 2025. Retail pharmacies' dominance reflects xerostomia's primarily outpatient, chronic symptom management nature - the majority of dry mouth products are purchased as recurring self-care items from community pharmacy and drugstore settings rather than through hospital dispensaries.

Major pharmacy chains, including CVS Pharmacy, Walgreens, Boots UK, and DM Drogerie Markt (Germany), stock dedicated dry mouth product sections, with pharmacist recommendation playing a significant role in product selection, given the condition's OTC-accessible management pathway. The growing integration of online pharmacy ordering with traditional retail chains further consolidates retail pharmacies' dominant distribution channel position, enabling convenient recurring purchase for chronic xerostomia management patients.

North America Xerostomia (Dry Mouth) Treatment Market Trends and Insights

North America leads the global Xerostomia Treatment market with approximately 37% of total market share in 2025, anchored by the United States' large aging population, high polypharmacy prevalence, significant head and neck cancer treatment volumes generating prescription xerostomia drug demand, and strong OTC consumer healthcare product adoption through established pharmacy retail networks. Growing ADA dentist awareness programs on xerostomia management are sustaining clinical recommendation rates for both prescription and OTC dry mouth products.

U.S. Xerostomia (Dry Mouth) Treatment Market Size

The United States accounts for approximately 88-90% of North American Xerostomia Treatment revenue, driven by approximately 65,000-70,000 annual head and neck cancer radiotherapy patients per the NCI, over 4 million Sjögren's syndrome patients per the Sjögren's Foundation, and widespread medication-induced xerostomia across the country's large chronically-medicated elderly population, the fastest-growing national demographic segment.

Europe Xerostomia (Dry Mouth) Treatment Market Trends and Insights

Europe is the second-largest Xerostomia Treatment market, supported by well-developed national healthcare systems that facilitate specialist referral for severe xerostomia cases, including oncology-related dry mouth and a growing consumer health awareness driving OTC dry mouth product adoption across European retail pharmacies. The European Association of Oral Medicine (EAOM) actively promotes clinical guidelines for managing xerostomia that support the adoption of structured treatment products across European dental and medical practices.

Germany Xerostomia (Dry Mouth) Treatment Market Size

Germany holds approximately 24% of the European Xerostomia Treatment market share, driven by the country's aging population, over 21% of Germans are aged 65+ per Destatis, high polypharmacy prevalence in elderly patients, and a well-developed oncology treatment infrastructure generating radiation-induced xerostomia cases. German pharmacy culture strongly supports pharmacist-directed dry-mouth product recommendations, thereby sustaining consistent OTC product sales volumes.

UK Xerostomia (Dry Mouth) Treatment Market Size

The United Kingdom accounts for approximately 19% of the European market revenue. NHS dental and oncology care pathways generate consistent demand for xerostomia treatment, and NICE guidelines on Sjögren's syndrome management and head and neck cancer supportive care include recommendations for xerostomia treatment. The Biotène® brand maintains strong U.K. retail pharmacy market penetration through Boots and independent pharmacy networks.

France Xerostomia (Dry Mouth) Treatment Market Size

France holds approximately 16% of the European Xerostomia Treatment market share. France's well-developed oncology treatment network, organized through comprehensive cancer centers (Centres de Lutte Contre le Cancer) generates significant radiation-induced xerostomia patient volumes. French dental associations and oncology societies actively promote xerostomia management protocols, supporting both prescription and OTC product procurement across hospital and retail pharmacy channels.

Asia Pacific Xerostomia (Dry Mouth) Treatment Market Trends and Insights

Asia Pacific is the fastest-growing xerostomia treatment market, driven by rapidly aging populations across China, Japan, India, and South Korea, increasing head and neck cancer diagnosis and treatment volumes, and growing pharmaceutical polypharmacy prevalence among elderly patients. China, where the National Cancer Center reports nasopharyngeal carcinoma (a major head and neck cancer requiring radiation) as among the most prevalent national cancer types, generates significant radiation-induced xerostomia demand, and expanding urban healthcare access is improving diagnosis and treatment rates for the condition.

Growing consumer awareness of oral health among middle-class urban populations in the region is also driving the adoption of OTC dry mouth products.

India Xerostomia (Dry Mouth) Treatment Market Size

India accounts for approximately 12-14% of the Asia Pacific Xerostomia Treatment market share, with a growing oral cancer and head and neck cancer burden. The Indian Council of Medical Research (ICMR) identifies oral cancer as among India's most prevalent cancers, generating radiation-related xerostomia cases. Expanding private dental and oncology clinic networks are improving dry mouth condition management uptake across urban Indian markets.

The Xerostomia (Dry Mouth) Treatment market is highly competitive, driven by strong demand for saliva substitutes, stimulants, OTC oral care products, and prescription therapies. Market participants focus on expanding product portfolios through advanced formulations such as long-lasting gels, sprays, lozenges, and mucoadhesive solutions that improve patient comfort and treatment adherence. Strategic priorities include innovation in drug delivery systems, partnerships with dental care providers, and stronger retail pharmacy presence.

Growing awareness of oral health, rising elderly populations, and increasing cancer-related dry mouth cases continue to intensify competition, while digital healthcare channels further support wider product accessibility and market penetration.

Key Developments:

• In September 2024, Saliwell developed the SaliPen, a device designed to stimulate natural saliva production for the treatment of dry mouth disease (xerostomia). SaliPen uses electro-stimulation, which the patients don’t feel, to increase saliva production. Its two flexible arms, equipped with stimulating electrodes, are placed in the mouth underneath the tongue.
• In January 2025, K Pharmaceuticals announced the first personalized xerostomia protocol (PXP) to address the growing dry mouth crisis.